Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.

Journal: Molecular oncology
PMID: 26778791

Abstract

BACKGROUND: Rationalization of antiangiogenics requires biomarkers. Vascular re-normalization is one widely accepted mechanism of action for this drug class. The interstitium of tumors with abnormal vasculature is hypoxic. We sought to track vascular normalization with (18)F-misonidazole ([18F]-FMISO, a probe that detects hypoxia) PET, in response to window-of-opportunity (WoO) treatment with the antiangiogenic dovitinib.

Authors

  • Elena Hernández-Agudo
    Breast Cancer Clinical Research Unit, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain.
  • Tamara Mondejar
    Breast Cancer Clinical Research Unit, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain.
  • Maria Luisa Soto-Montenegro
    Unidad de Medicina y Cirugía Experimental, Instituto de Investigación Sanitaria Gregorio Marañon, Doctor Esquerdo, 46, Madrid, 28007, Spain; CIBER de Salud Mental, Monforte de Lemos 3-5, Pabellón 11, Madrid, 28029, Spain.
  • Diego Megías
    Confocal Microscopy Unit, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain.
  • Silvana Mouron
    Breast Cancer Clinical Research Unit, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain.
  • Jesus Sanchez
    Breast Cancer Clinical Research Unit, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain.
  • Manuel Hidalgo
    Gastrointestinal Cancer Clinical Research Unit, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain.
  • Pedro Pablo Lopez-Casas
    Gastrointestinal Cancer Clinical Research Unit, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain.
  • Francisca Mulero
    Molecular Imaging Unit, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain.
  • Manuel Desco
    Unidad de Medicina y Cirugía Experimental, Instituto de Investigación Sanitaria Gregorio Marañon, Doctor Esquerdo, 46, Madrid, 28007, Spain; CIBER de Salud Mental, Monforte de Lemos 3-5, Pabellón 11, Madrid, 28029, Spain; Aerospace Engineering and Bioengineering Department, Universidad Carlos III, Avenida de la Universidad, 30. Leganés, Madrid, 28911, Spain.
  • Miguel Quintela-Fandino
    Breast Cancer Clinical Research Unit, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, Madrid, 28029, Spain. Electronic address: mquintela@cnio.es.

Keywords

External Resources

Popular Topics
Recent Journals